{"id":61235,"date":"2025-05-10T16:02:28","date_gmt":"2025-05-10T14:02:28","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/nanyang-biologics-and-precisya-global-inc-announce-strategic-collaboration-to-validate-natural-compounds-against-genetic-disease-markers\/"},"modified":"2025-05-10T16:02:28","modified_gmt":"2025-05-10T14:02:28","slug":"nanyang-biologics-and-precisya-global-inc-announce-strategic-collaboration-to-validate-natural-compounds-against-genetic-disease-markers","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/nanyang-biologics-and-precisya-global-inc-announce-strategic-collaboration-to-validate-natural-compounds-against-genetic-disease-markers\/","title":{"rendered":"Nanyang Biologics and Precisya Global Inc Announce Strategic Collaboration to Validate Natural Compounds Against Genetic Disease Markers"},"content":{"rendered":"
\n

SINGAPORE & WILMINGTON, Del.–(BUSINESS WIRE)–Nanyang Biologics (NYB) and Precisya Global Inc (PGI) announce a strategic collaboration to leverage our technologies in validating potential therapeutic benefits of natural compounds against genetically identified risk factors and predispositions for chronic diseases. The partnership combines PGI’s genomic big data analytics with NYB’s natural compound libraries and AI capabilities.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\nThe collaboration will leverage DTIGN (Drug-Target Interaction Graph Neural Network), NYB\u2019s proprietary AI model that has demonstrated a 27.03% improvement in prediction accuracy over leading methods. DTIGN significantly enhances the identification of active compounds and shortens early-stage discovery timelines. This technology will be used to screen compounds as NYB continues to build one of the world\u2019s largest natural compound libraries, unlocking novel therapeutic opportunities with exceptional precision and speed.\n<\/p>\n

\nAs a key contributor to this strategic partnership, Precisya Global Inc will utilize advanced genomic data analysis platforms and specialized genetic knowledge from 22+ Million Scientific Publications<\/a> <\/b>to identify disease-relevant biomarkers. The company will provide secure access to anonymized patient genomic data in compliance with privacy regulations, while offering expert bioinformatic analysis of correlations between natural compound responses and genetic variants.\n<\/p>\n

\nThis joint initiative bridges the gap between genomic analysis and natural compound research, aiming to accelerate the discovery of nature-based treatments for genetic diseases through AI-driven matching and rigorous validation processes. This enables personalized nature-based treatments for individuals with genetic health conditions, offering better outcomes, fewer side effects, and more affordable options.\n<\/p>\n

\n“This collaboration represents a significant advancement in precision medicine,”<\/i> said Roland Ong, Founder and Chairman of Nanyang Biologics. “By combining our natural compound expertise and DTIGN technology with PGI’s genomic capabilities, we aim to develop more targeted and effective treatments while significantly reducing the time and cost typically associated with drug discovery.”<\/i>\n<\/p>\n

\nThe partnership includes comprehensive validation through in vitro and in vivo assays, supported by joint biobanks and patient samples. This integrated approach ensures robust validation of potential therapeutic compounds while maintaining high scientific standards.\n<\/p>\n

\nAbout Precisya Global Inc:<\/b>\n<\/p>\n

\nPrecisya Global Inc (PGI) is a leading deep health tech company with its genomic big data and unique algorithms that maps the genetic interference pattern across the whole body metabolic pathway, identifying the causative and associative factors of chronic disease expressions Through PGI state-of-the-art technology platform and comprehensive genomic database, PGI delivers precise, data-driven insights that enable personalized healthcare solutions and accelerate plant based compounds drug development processes.\n<\/p>\n

\nAbout Nanyang Biologics<\/b>\n<\/p>\n

\nNanyang Biologics (NYB) is a biotech company using AI and biological data to understand drug-target interactions in disease pathways. Through its AI platform and compound libraries<\/a>, NYB identifies promising therapeutic molecules and optimizes them for effectiveness. Using advanced machine learning techniques, NYB accelerates the discovery of next-generation treatments for cancer and chronic diseases.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nFor media inquiries:
\n
Quynh Nguyen<\/b>
Senior AI Partnership Manager
\n
Nanyang Biologics
\n
quynh@nanyangbiologics.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SINGAPORE & WILMINGTON, Del.–(BUSINESS WIRE)–Nanyang Biologics (NYB) and Precisya Global Inc (PGI) announce a strategic collaboration to leverage our technologies in validating potential therapeutic benefits of natural compounds against genetically identified risk factors and predispositions for chronic diseases. The partnership combines PGI’s genomic big data analytics with NYB’s natural compound libraries and AI capabilities. The … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-61235","6":"format-standard","7":"category-industry"},"yoast_head":"\nNanyang Biologics and Precisya Global Inc Announce Strategic Collaboration to Validate Natural Compounds Against Genetic Disease Markers - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/nanyang-biologics-and-precisya-global-inc-announce-strategic-collaboration-to-validate-natural-compounds-against-genetic-disease-markers\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanyang Biologics and Precisya Global Inc Announce Strategic Collaboration to Validate Natural Compounds Against Genetic Disease Markers - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SINGAPORE & WILMINGTON, Del.–(BUSINESS WIRE)–Nanyang Biologics (NYB) and Precisya Global Inc (PGI) announce a strategic collaboration to leverage our technologies in validating potential therapeutic benefits of natural compounds against genetically identified risk factors and predispositions for chronic diseases. The partnership combines PGI’s genomic big data analytics with NYB’s natural compound libraries and AI capabilities. The ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/nanyang-biologics-and-precisya-global-inc-announce-strategic-collaboration-to-validate-natural-compounds-against-genetic-disease-markers\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-10T14:02:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250508997180\/en\/2464102\/22\/Precisya_partnership.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanyang-biologics-and-precisya-global-inc-announce-strategic-collaboration-to-validate-natural-compounds-against-genetic-disease-markers\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanyang-biologics-and-precisya-global-inc-announce-strategic-collaboration-to-validate-natural-compounds-against-genetic-disease-markers\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Nanyang Biologics and Precisya Global Inc Announce Strategic Collaboration to Validate Natural Compounds Against Genetic Disease Markers\",\"datePublished\":\"2025-05-10T14:02:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanyang-biologics-and-precisya-global-inc-announce-strategic-collaboration-to-validate-natural-compounds-against-genetic-disease-markers\\\/\"},\"wordCount\":488,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanyang-biologics-and-precisya-global-inc-announce-strategic-collaboration-to-validate-natural-compounds-against-genetic-disease-markers\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250508997180\\\/en\\\/2464102\\\/22\\\/Precisya_partnership.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanyang-biologics-and-precisya-global-inc-announce-strategic-collaboration-to-validate-natural-compounds-against-genetic-disease-markers\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanyang-biologics-and-precisya-global-inc-announce-strategic-collaboration-to-validate-natural-compounds-against-genetic-disease-markers\\\/\",\"name\":\"Nanyang Biologics and Precisya Global Inc Announce Strategic Collaboration to Validate Natural Compounds Against Genetic Disease Markers - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanyang-biologics-and-precisya-global-inc-announce-strategic-collaboration-to-validate-natural-compounds-against-genetic-disease-markers\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanyang-biologics-and-precisya-global-inc-announce-strategic-collaboration-to-validate-natural-compounds-against-genetic-disease-markers\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250508997180\\\/en\\\/2464102\\\/22\\\/Precisya_partnership.jpg\",\"datePublished\":\"2025-05-10T14:02:28+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanyang-biologics-and-precisya-global-inc-announce-strategic-collaboration-to-validate-natural-compounds-against-genetic-disease-markers\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanyang-biologics-and-precisya-global-inc-announce-strategic-collaboration-to-validate-natural-compounds-against-genetic-disease-markers\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanyang-biologics-and-precisya-global-inc-announce-strategic-collaboration-to-validate-natural-compounds-against-genetic-disease-markers\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250508997180\\\/en\\\/2464102\\\/22\\\/Precisya_partnership.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250508997180\\\/en\\\/2464102\\\/22\\\/Precisya_partnership.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanyang-biologics-and-precisya-global-inc-announce-strategic-collaboration-to-validate-natural-compounds-against-genetic-disease-markers\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanyang Biologics and Precisya Global Inc Announce Strategic Collaboration to Validate Natural Compounds Against Genetic Disease Markers\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanyang Biologics and Precisya Global Inc Announce Strategic Collaboration to Validate Natural Compounds Against Genetic Disease Markers - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/nanyang-biologics-and-precisya-global-inc-announce-strategic-collaboration-to-validate-natural-compounds-against-genetic-disease-markers\/","og_locale":"en_US","og_type":"article","og_title":"Nanyang Biologics and Precisya Global Inc Announce Strategic Collaboration to Validate Natural Compounds Against Genetic Disease Markers - Pharma Trend","og_description":"SINGAPORE & WILMINGTON, Del.–(BUSINESS WIRE)–Nanyang Biologics (NYB) and Precisya Global Inc (PGI) announce a strategic collaboration to leverage our technologies in validating potential therapeutic benefits of natural compounds against genetically identified risk factors and predispositions for chronic diseases. The partnership combines PGI’s genomic big data analytics with NYB’s natural compound libraries and AI capabilities. The ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/nanyang-biologics-and-precisya-global-inc-announce-strategic-collaboration-to-validate-natural-compounds-against-genetic-disease-markers\/","og_site_name":"Pharma Trend","article_published_time":"2025-05-10T14:02:28+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250508997180\/en\/2464102\/22\/Precisya_partnership.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/nanyang-biologics-and-precisya-global-inc-announce-strategic-collaboration-to-validate-natural-compounds-against-genetic-disease-markers\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/nanyang-biologics-and-precisya-global-inc-announce-strategic-collaboration-to-validate-natural-compounds-against-genetic-disease-markers\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Nanyang Biologics and Precisya Global Inc Announce Strategic Collaboration to Validate Natural Compounds Against Genetic Disease Markers","datePublished":"2025-05-10T14:02:28+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/nanyang-biologics-and-precisya-global-inc-announce-strategic-collaboration-to-validate-natural-compounds-against-genetic-disease-markers\/"},"wordCount":488,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/nanyang-biologics-and-precisya-global-inc-announce-strategic-collaboration-to-validate-natural-compounds-against-genetic-disease-markers\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250508997180\/en\/2464102\/22\/Precisya_partnership.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/nanyang-biologics-and-precisya-global-inc-announce-strategic-collaboration-to-validate-natural-compounds-against-genetic-disease-markers\/","url":"https:\/\/pharma-trend.com\/en\/nanyang-biologics-and-precisya-global-inc-announce-strategic-collaboration-to-validate-natural-compounds-against-genetic-disease-markers\/","name":"Nanyang Biologics and Precisya Global Inc Announce Strategic Collaboration to Validate Natural Compounds Against Genetic Disease Markers - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/nanyang-biologics-and-precisya-global-inc-announce-strategic-collaboration-to-validate-natural-compounds-against-genetic-disease-markers\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/nanyang-biologics-and-precisya-global-inc-announce-strategic-collaboration-to-validate-natural-compounds-against-genetic-disease-markers\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250508997180\/en\/2464102\/22\/Precisya_partnership.jpg","datePublished":"2025-05-10T14:02:28+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/nanyang-biologics-and-precisya-global-inc-announce-strategic-collaboration-to-validate-natural-compounds-against-genetic-disease-markers\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/nanyang-biologics-and-precisya-global-inc-announce-strategic-collaboration-to-validate-natural-compounds-against-genetic-disease-markers\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/nanyang-biologics-and-precisya-global-inc-announce-strategic-collaboration-to-validate-natural-compounds-against-genetic-disease-markers\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250508997180\/en\/2464102\/22\/Precisya_partnership.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250508997180\/en\/2464102\/22\/Precisya_partnership.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/nanyang-biologics-and-precisya-global-inc-announce-strategic-collaboration-to-validate-natural-compounds-against-genetic-disease-markers\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Nanyang Biologics and Precisya Global Inc Announce Strategic Collaboration to Validate Natural Compounds Against Genetic Disease Markers"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61235","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=61235"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61235\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=61235"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=61235"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=61235"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}